



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Kai-Uwe Lewandrowski
✉ business@tucsonspine.com
Kenneth Blum
✉ drd2gene@gmail.com

RECEIVED 31 October 2025
ACCEPTED 03 November 2025
PUBLISHED 17 November 2025

CITATION
Lewandrowski K-U, Blum K,
Lewandrowski APL, Thanos PK, Pinhasov A,
Sharafshah A, Baron D, Gold MS, Dennen CA,
Elman I, Bowirrat A, Modestino EJ, Zeine F,
Jafari N, Sunder K, Makale MT, Giordano J,
Gondre-Lewis MC, Lindenau M, Fuehrlein BS,
Badgaiyan RD, Levin C, Schmidt SL and
Fiorelli RKA (2025) Correction: Targeting
pro-dopaminergic agonism to attenuate
depression in patients displaying
genetic/epigenetic predisposition to
hypodopaminergia.
Front. Public Health 13:1737084.
doi: 10.3389/fpubh.2025.1737084

COPYRIGHT
© 2025 Lewandrowski, Blum, Lewandrowski,
Thanos, Pinhasov, Sharafshah, Baron, Gold,
Dennen, Elman, Bowirrat, Modestino, Zeine,
Jafari, Sunder, Makale, Giordano,
Gondre-Lewis, Lindenau, Fuehrlein,
Badgaiyan, Levin, Schmidt and Fiorelli. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia

Kai-Uwe Lewandrowski^{1,2,3,4,5*}, Kenneth Blum^{1,6,7,8,9,10,11,12*},
Alexander P. L. Lewandrowski¹³, Panayotis K. Thanos^{6,14},
Albert Pinhasov^{1,6}, Alireza Sharafshah^{1,15}, David Baron^{1,7,16},
Mark S. Gold¹⁷, Catherine A. Dennen^{1,18}, Igor Elman^{1,6,19},
Aballa Bowirrat^{1,6}, Edward J. Modestino^{1,8}, Foojan Zeine^{1,8,20},
Nicole Jafari^{1,8,21}, Keerthy Sunder^{1,7,12,22}, Milan T. Makale^{1,8,23},
John Giordano^{1,8,9}, Marjorie C. Gondre-Lewis^{1,24},
Marco Lindenau¹, Brian S. Fuehrlein²⁵,
Rajendra D. Badgaiyan^{1,8,26,27}, Chynna Levin^{1,8,28},
Sergio Luis Schmidt⁴ and Rossano Kepler Alvim Fiorelli⁴

¹Division of Personalized Genomics, The Blum Institute of Neurogenetics & Behavior, Austin, TX, United States, ²Department of Orthopedic Surgery, University of Arizona Tucson Campus, Tucson, AZ, United States, ³Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, Colombia, ⁴Department of Orthopedics, Hospital Universitário Gaffree Guinle Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁵Division of Personalized Pain Research and Education, Center for Advanced Spine Care of Southern Arizona, Tucson, AZ, United States, ⁶Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel, ⁷Division of Addiction Research & Education, Center for Sports, Exercise, and Mental Health, Western University of Health Sciences, Pomona, CA, United States, ⁸Brain & Behavior Lab, Department of Psychology, Curry College, Milton, MA, United States, ⁹Division of Recovery and Rehabilitation, JC Recovery and Counseling Center, Hollywood, FL, United States, ¹⁰Faculty of Education and Psychology, Institute of Psychology, Eötvös Loránd University, Budapest, Hungary, ¹¹Department of Psychiatry, University of Vermont, Burlington, VT, United States, ¹²Division of Neuromodulation Research, Karma Doctors & Karma TMS, Palm Springs, CA, United States, ¹³Department of Biological Sciences, Dornsife College of Letters, Arts & Sciences, University of Southern California, Los Angeles, CA, United States, ¹⁴Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Clinical Research Institute on Addictions, State University of New York at Buffalo, Buffalo, NY, United States, ¹⁵Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran, ¹⁶Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, United States, ¹⁷Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States, ¹⁸Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, United States, ¹⁹Department of Psychiatry, Cambridge Alliance, Harvard University School of Medicine, Cambridge, MA, United States, ²⁰Department of Health Science, California State University at Long Beach, Long Beach, CA, United States, ²¹Department of Applied Clinical Psychology, The Chicago School of Professional Psychology, Los Angeles, CA, United States, ²²Department of Psychiatry, University of California, Riverside, Riverside, CA, United States, ²³Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA, United States, ²⁴Department of Anatomy, Howard University College of Medicine, Washington, DC, United States, ²⁵Department of Psychiatry, Yale University, New Haven, CT, United States, ²⁶Department of Psychiatry, School of Medicine, Texas Tech University Health Sciences Center, Midland, TX, United States, ²⁷Department of Psychiatry, Mt. Sinai University School of Medicine, New York, NY, United States, ²⁸Department of Clinical Psychology, St. John's University, Queens, NY, United States

KEYWORDS

dopamine D2 receptor (DRD2), hypodopaminergia, pro-dopaminergic therapy, stress induced anxiety, genetic predisposition, Reward Deficiency Syndrome (RDS), neurotransmitter regulation, addiction and mood disorders

A Correction on

Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia

by Lewandrowski, K.-U., Blum, K., Lewandrowski, A. P. L., Thanos, P. K., Pinhasov, A., Sharafshah, A., Baron, D., Gold, M. S., Dennen, C. A., Elman, I., Bowirrat, A., Modestino, E. J., Zeine, F., Jafari, N., Sunder, K., Makale, M. T., Giordano, J., Gondre-Lewis, M. C., Lindenau, M., Fuehrlein, B. S., Badgaiyan, R. D., Levin, C., Schmidt, S. L., and Fiorelli, R. K. A. (2025). *Front. Public Health* 13:1594872. doi: 10.3389/fpubh.2025.1594872

The title of this article was erroneously given as “Targeting pro-dopaminergic agonism to attenuate and depression

in patient’s displaying genetic/epigenetic predisposition to hypodopaminergia.”

The correct title of the article is “Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia.”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.